Drug Trial Radar · NCT07695597
A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia
Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Jul 15, 2026
Primary completion
Apr 30, 2027
Study completion Sep 10, 2027
Sponsor
- Lead sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-parallel, multicenter phase II clinical trial to evaluate the efficacy and safety of SYH2070 injection in participants with mixed hyperlipidemia.
Conditions
- Mixed Hyperlipidemia
Interventions
SYH2070Drug
SYH2070 injection, 150 mg, 300 mg, 400 mg, SC, administration duration: 24 weeks
PlaceboDrug
Placebo, SC, administration duration: 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percentage change in serum TG levels from baseline at week 24Time frame: Baseline through Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.